Frequently asked questions

Are the drugs safe?
All of our products are extensively tested to ensure their safety. They cannot be marketed until evidence of their safety is provided and FDA and/or EMA approval has been granted. Furthermore, the fact that they are taken ‘on demand’ rather than routinely ensures that any mild side effects are only temporary.

How will I know if my patients need Lybrido or Lybridos?
Emotional Brain has developed an algorithm to help differentiate between Lybrido and Lybridos responders.

Is FSD a common problem? How many women suffer from FSD?
According to the Journal of the American Medical Association, approximately 43% of adult women suffer from FSD at some point in their life. Experts say it is a widespread and unmet medical need.

When will women be able to buy the new drugs?
Provided that FDA approval is obtained, we expect that Lybrido and Lybridos can be launched in the market by 2015.

What are the drugs going to cost?
We will do everything within our power to ensure that these new drugs will be affordable and reasonably priced.

Why are the Phase 2B studies being conducted in the United States of America?
As FSD/HSDD is a problem affecting millions of women all over the globe, we feel that it is important to obtain global registration. Obtaining FDA approval is the shortest route to ensuring global marketing.

How can I participate in a trial?
If you are interested in participating in one of our clinical trials, please visit our website www.lybrido.nl for the Netherlands, or send an email to info@ebnewyork.com for the United States.

Does Emotional Brain also perform research on men?
Emotional Brain currently focuses predominantly on female sexual disorders, but future research involving male subjects is not excluded.

Information about investment
Emotional Brain is interested in finding potential investors and strategic partners for further clinical development and commercialization of our products. Details are available at the Shareholders page. 

Is FSD a real disease?
FSD is described in the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, commonly referred to as DSM-IV. This means that it is generally recognized as a real medical condition.